Core Thesis - LeMaitre Vascular, Inc. (LMAT) is positioned as a compelling long-term investment opportunity in the niche medical device sector, driven by disciplined execution and multiple growth levers [6]. Company Overview - LeMaitre Vascular has transformed from a small manufacturer in Massachusetts to a profitable player in the global medical device industry, focusing on peripheral vascular surgery [2]. - The company boasts a portfolio of over 100 specialized devices and employs a dedicated direct-to-hospital sales force, complemented by a serial acquisition strategy [2]. Financial Performance - For 2025, LeMaitre is projected to achieve net sales of $249.6 million and operating income of $57.73 million, with Q4 margins at 29.2% and a 21% return on invested capital [4]. - The guidance for 2026 anticipates sales of $280 million and operating income of $77.8 million, supported by a $100 million share repurchase program and increased dividends [4]. Growth Drivers - The biologics platform, particularly Artegraft, is the fastest-growing segment, contributing to category expansion with higher-margin products and an international rollout ahead of schedule [3]. - The company benefits from multiple growth engines, including organic sales, acquisitions, biologics expansion, and international penetration, which collectively enhance value [5]. Market Position - LeMaitre operates in a structurally growing market characterized by demographic trends, increasing prevalence of peripheral vascular diseases, and a shift towards complex procedures that favor specialist expertise [5]. - The company maintains strong relationships with vascular surgeons, creating consistent demand and high-value sales interactions, unlike larger medical device conglomerates [3].

LMAT Investor Presentation Disclaimers Unaudited Financial Results The quarterly financial results in this document are unaudited. Large and Growing Global Sales Force Forward-Looking Statements This document contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events described in forward- looking statements. Factors that might cau ...

Financial Data and Key Metrics Changes - Q4 2025 featured 16% sales growth, a gross margin of 71.7%, and a 47% increase in operating income [4] - Q4 fully diluted earnings per share were $0.68, representing a 39% year-over-year increase [8] - For the full year 2025, organic revenue growth was 14%, with adjusted gross margin at 70.4% and adjusted EPS growth of 23% [9] Business Line Data and Key Metrics Changes - Sales growth in Q4 was led by grafts (up 27%), valvetomes (up 20%), and shunts (up 18%) [4] - RFA Vascular grew 19% and RFA Cardiac grew 90% in Q4 [4] - Autograft sales grew 29% worldwide in Q4, with international sales reaching $1.9 million in Q4 and $4 million for the full year 2025 [4][9] Market Data and Key Metrics Changes - EMEA region sales grew 29%, APAC grew 20%, and the Americas grew 10% in Q4 [4] - International sales of autograft are expected to reach approximately $10 million in 2026, contributing $6 million of sales growth for the year [4] Company Strategy and Development Direction - The company aims to produce quality devices, build its vascular sales force, go direct in new countries, acquire niche products, and focus on profitability, cash flow, and dividends [7] - The company plans to consolidate its Chicago RFA facility into Burlington in 2026 to simplify operations and reduce costs [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating 12% sales growth and 21% adjusted operating income growth [6][11] - The company experienced a cyber incident in January 2026 but reported minimal disruption to sales and manufacturing [9][10] Other Important Information - The board approved a new $100 million share repurchase program and a Q1 2026 dividend of $0.25 per share, marking the 15th consecutive year of dividend increases [10] - The company ended 2025 with $359 million in cash and securities, with free cash flow of $74.5 million [9] Q&A Session Summary Question: Can you rank the factors key to achieving operating growth? - Management highlighted stable headcount, sales pricing growth, and improved manufacturing efficiency as key factors for operating leverage [16] Question: What contributed to the smoother price transition this year? - Management noted that sending price lists earlier allowed for better preparation among sales and customer service teams, leading to a smoother transition [17] Question: What is the setup for M&A in 2026? - Management indicated a focus on organic growth but remains open to M&A opportunities, particularly in the open vascular area [28][30] Question: Can you elaborate on the performance of Artegraft? - Management revised the total addressable market (TAM) for Artegraft in Europe to $30 million, indicating stronger than expected performance [33] Question: How is the company performing in China? - Management reported a 24% revenue increase in Q4, with profitability achieved for the first time in the region [47] Question: What is the outlook for gross margin in 2026? - Management expects gross margin to increase by 170 basis points from 2025 to 2026, driven by pricing increases and manufacturing efficiencies [75] Question: What is the anticipated impact of the Restore Flow manufacturing transfer? - Management indicated it may be a slight headwind to margins in 2026 as operations transition [96]

Financial Data and Key Metrics Changes - Q4 2025 featured 16% sales growth, with a gross margin of 71.7% and operating income growth of 47% [4] - Q4 fully diluted earnings per share (EPS) were $0.68, a 39% increase year-over-year [8] - For the full year 2025, organic revenue growth was 14%, with adjusted EPS growth of 23% [9] Business Line Data and Key Metrics Changes - Sales growth in Q4 was led by grafts (up 27%), valvulotomes (up 20%), and shunts (up 18%) [4] - RFA Vascular grew 19% and RFA Cardiac grew 90% in Q4 [4] - Artegraft grew 29% worldwide in Q4, with international sales reaching $1.9 million in Q4 and $4 million for the full year 2025 [4] Market Data and Key Metrics Changes - EMEA region grew 29%, APAC grew 20%, and the Americas grew 10% in Q4 [4] - International sales are expected to reach approximately $10 million in 2026, contributing $6 million of sales growth for the year [4] Company Strategy and Development Direction - The company aims to produce quality devices, build its vascular sales force, go direct in new countries, acquire niche products, and focus on profitability, cash flow, and dividends [7] - The 2026 U.S. price list reflects a blended 8% increase across the portfolio, with early results indicating hospital acceptance [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating 12% sales growth and 21% adjusted operating income growth [9] - The company is focused on niche markets and believes it is well-positioned for another successful year in 2026 [12] Other Important Information - The company ended 2025 with $359 million in cash and securities, and free cash flow for the year was $74.5 million [9] - A cyber incident in January 2026 had minimal impact on sales and operations, with adequate insurance coverage [10] Q&A Session Summary Question: Factors for achieving operating growth in 2026 - Management highlighted stable headcount, sales pricing growth, and improved manufacturing efficiency as key factors for operating leverage [16] Question: Outlook for future price increases - Management noted that the smoother transition for price increases this year was due to earlier communication and preparation [17][19] Question: M&A strategy and targets - The company is actively pursuing M&A opportunities in open vascular and cardiac surgery, with a focus on revenues between $15 million and $150 million [30][31] Question: Performance of Artegraft and market potential - Management revised the total addressable market (TAM) for Artegraft in Europe to $30 million, indicating stronger than expected performance [33] Question: Updates on the European market and MDR approvals - The company has been aggressive with MDR approvals, gaining market share as competitors faced challenges [44][46] Question: Performance in China - Revenue in China grew 24% in Q4, with the company now profitable in that market for the first time [47][48] Question: Valvulotome sales growth - Management attributed the 20% growth in valvulotomes to a well-established sales channel and effective marketing [50][56] Question: Guidance for 2026 tax rate and share count - The tax rate for 2026 is expected to be around 23.2%, with share count remaining stable [100] Question: Approval status for RestoreFlow in Ireland - Approval for RestoreFlow in Ireland is now expected in Q3 2026, delayed from previous expectations [103]

Financial Data and Key Metrics Changes - Q4 2025 featured 16% sales growth, with a gross margin of 71.7% and operating income growth of 47% [4] - Q4 fully diluted earnings per share were $0.68, a 39% increase year-over-year [9] - For the full year 2025, organic revenue growth was 14%, with adjusted gross margin at 70.4% and adjusted EPS growth of 23% [10] Business Line Data and Key Metrics Changes - Sales growth in Q4 was led by grafts (up 27%), valvetomes (up 20%), and shunts (up 18%) [4] - RFA Vascular grew 19% and RFA Cardiac grew 90% in Q4 [4] - Autograft sales grew 29% worldwide in Q4, with international sales reaching $1.9 million in Q4 and $4 million for the full year 2025 [4] Market Data and Key Metrics Changes - EMEA region sales grew 29%, APAC grew 20%, and the Americas grew 10% in Q4 [4] - International sales of autograft are expected to reach approximately $10 million in 2026, contributing $6 million of sales growth for the year [4] Company Strategy and Development Direction - The company aims to produce quality devices, build its vascular sales force, go direct in new countries, acquire niche products, and focus on profitability, cash flow, and dividends [7] - The 2026 U.S. price list reflects a blended 8% increase across the portfolio, with early results indicating hospital acceptance [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating revenue of $280 million, organic sales growth of 12%, and operating income of $77.8 million, up 21% adjusted from 2025 [12] - The company experienced a cyber incident in January 2026 but reported minimal disruption to sales and manufacturing [10][11] Other Important Information - The board approved a new $100 million share repurchase program and a Q1 2026 dividend of $0.25 per share, marking the 15th consecutive year of dividend increases [11] - The company ended 2025 with $359 million in cash and securities, with free cash flow of $74.5 million [10] Q&A Session Summary Question: Guidance and Operating Growth Factors - Management highlighted stable headcount, sales pricing growth, and manufacturing efficiencies as key factors for achieving operating growth above sales growth [15][16] Question: Price Increases and Future Outlook - Management noted that the smoother transition for price increases this year was due to earlier communication and preparation [18][19] Question: M&A Environment and Strategy - The company is actively pursuing M&A opportunities, focusing on open vascular and cardiac surgery markets, with 22 targets identified [30][32] Question: Artegraft Performance and Market Potential - Management revised the total addressable market (TAM) for Artegraft in Europe to $30 million, indicating stronger than expected performance [34][35] Question: Impact of CREST-2 Trial on Carotid Business - Management stated that the carotid shunt business remains resilient and is transitioning to an OUS business model [70][72] Question: Gross Margin Outlook - Management expects continued gross margin improvement, with guidance for a 170 basis point increase from 2025 to 2026 [80][82] Question: Restore Flow Manufacturing Transfer - The transfer of Restore Flow manufacturing is expected to be a slight headwind to margins in 2026, with costs already included in guidance [102]

Core Insights - LeMaitre Vascular, Inc. reported strong Q3 2025 results, driven by significant sales growth in grafts and shunts, and announced a quarterly dividend of $0.20 per share [1][5][3] Financial Performance - Q3 2025 sales reached $61.0 million, representing an 11% increase year-over-year, with organic growth of 12% [8][22] - Adjusted gross margin improved to 70.8%, up from 67.8% in Q3 2024, attributed to higher average selling prices and manufacturing efficiencies [3][8] - Adjusted operating income was $16.9 million, a 29% increase, benefiting from moderating operating expenses [3][8] - Net income for Q3 2025 was $17.4 million, compared to $11.1 million in Q3 2024, reflecting a 56% increase [20][21] Sales Growth Drivers - Grafts and shunts were key contributors to sales growth, with grafts increasing by 23% and shunts by 18% [3] - Artegraft experienced accelerated growth of 33% due to its international launch [3] - Sales in the EMEA region increased by 18%, the Americas by 10%, and APAC by 4% [3] Business Outlook - For Q4 2025, the company expects sales between $61.8 million and $63.8 million, with full-year guidance set at $247 million to $249 million, both reflecting a 13% increase [4] - Gross margin is projected at 71.2% for Q4 and 71.4% for the full year [4] - Adjusted EPS for Q4 is expected to be between $0.64 and $0.69, with full-year guidance of $2.48 to $2.53, indicating a 30% increase [4] Dividend and Share Repurchase - The Board of Directors approved a quarterly dividend of $0.20 per share, payable on December 4, 2025 [5] - A share repurchase program was authorized for up to $75 million, set to conclude on February 17, 2026, unless extended [6] Company Overview - LeMaitre Vascular specializes in vascular devices, implants, and services for treating peripheral vascular disease, a condition affecting over 200 million people globally [11]

Core Viewpoint - LeMaitre Vascular, Inc. reported strong Q1 2025 results with significant sales growth driven by grafts and carotid shunts, and provided an optimistic sales guidance for the year ahead [1][5]. Financial Performance - Q1 2025 net sales reached $59.9 million, reflecting a 12% increase compared to Q1 2024, with organic growth at 13% [10][21]. - Gross margin improved to 69.2%, up from 68.6% in Q1 2024, attributed to higher average selling prices and manufacturing efficiencies [3][10]. - Operating income was $12.6 million, a 6% increase year-over-year, while operating expenses grew by 16% primarily due to personnel costs [3][10]. - Net income for Q1 2025 was $11.0 million, compared to $9.9 million in Q1 2024, with diluted earnings per share at $0.48, up 10% [21][22]. Sales Growth Drivers - Sales growth was driven by a 17% increase in grafts and a 14% increase in carotid shunts, with regional sales growth of 18% in EMEA, 11% in the Americas, and 3% in APAC [3][10]. - Artegraft, the largest U.S. product, generated $37 million in sales in 2024 and received its MDR CE Mark on April 29, 2025, with a European launch imminent [4]. Guidance and Strategic Initiatives - The company raised its 2025 sales guidance to $245 million, with an organic growth forecast of 13%, up from previous guidance of $239 million and 10% organic growth [5]. - Q2 2025 guidance includes projected sales of $61.5 million to $63.5 million, with a gross margin of 69.5% and operating income between $14.6 million and $16.0 million [5]. Dividend and Share Repurchase - A quarterly dividend of $0.20 per share was approved, to be paid on May 29, 2025 [7]. - The company has authorized a share repurchase program of up to $75 million, which may be suspended or discontinued at any time [8].

Financial Data and Key Metrics Changes - In Q4 2024, the company reported a sales growth of 14%, operating income growth of 26%, and earnings per share (EPS) growth of 30% [6] - Gross margin increased by 120 basis points year-over-year to 69.3% due to higher average selling prices (ASPs), direct labor efficiencies, and improved RestoreFlow Allograft yields [15][17] - Operating income for Q4 2024 was $12.9 million, reflecting a 26% year-over-year increase, with an operating margin of 23% [17] - The company ended Q4 2024 with $300 million in cash and securities, an increase of $176 million in the quarter [17] Business Line Data and Key Metrics Changes - Sales growth was driven by grafts, shunts, and catheters, which increased by 23%, 14%, and 12% respectively [6] - Artegraft, XenoSure, and RestoreFlow were highlighted as key products contributing to price improvements [14] - The shunts category experienced a strong year with a 14% increase, attributed to competitors exiting the market [108] Market Data and Key Metrics Changes - By geography, sales in the Asia-Pacific (APAC) region grew by 21%, EMEA by 18%, and the Americas by 12% in Q4 [6] - The company received its Chinese XenoSure cardiac approval in December, with sales in China up 48% in Q4 [8] Company Strategy and Development Direction - The company plans to expand its sales team from 152 representatives to 165 by the end of 2025, focusing on both U.S. and international markets [7][34] - New international sales offices have been established, including a new office in Shanghai, which began shipping products to Chinese customers [8][9] - The company is pursuing direct-to-hospital sales in Portugal and Czechia, with expectations to begin in H2 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the sales force being the company's number one asset and plans to continue investing in sales managers and offices [7] - The company anticipates organic sales growth of 10% for the full year 2025, with a gross margin of 69.7% and operating income of $59.8 million, reflecting a 15% increase [21] - Management acknowledged the challenges of providing guidance in the medical device sector but noted a history of overperforming guidance in recent years [50] Other Important Information - The Board of Directors approved a cash dividend of $0.20 per share per quarter, an increase of 25% [20] - The company has received 16 of the 23 MDR CE marks, with expectations to receive the remaining approvals in 2025 [10][11] Q&A Session Summary Question: Can you talk about guidance and pricing? - Management indicated that historical pricing increases have been higher than expected, but they anticipate a more conservative approach moving forward, estimating around 6% pricing and 4% unit growth [25][26] Question: Can you provide details on salesforce expansion? - The company plans to add approximately 165 reps by the end of 2025, with two-thirds of the growth expected in the U.S. [34][36] Question: What are the expectations for Artegraft's market opportunity? - Artegraft is expected to contribute significantly to growth, with a market opportunity of $8 million in Europe, but management refrained from providing specific guidance until after approval [40][41] Question: What is the impact of tariffs on the company? - Management noted that most products are manufactured in the U.S., so tariffs would have a minimal impact, with China accounting for less than 1% of worldwide sales [81][82] Question: What is the strategy for the Ireland facility? - The company is committed to establishing a physical presence in Ireland to pursue approvals, with expectations for at least one approval in 2025 [96][98]